CancerDrs

Breast Cancer clinical trials in Maryland

33 actively recruiting breast cancer trials at 24 sites across Maryland.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Maryland:
  • University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
  • Greater Baltimore Medical Center — Baltimore, Maryland
  • Sinai Hospital of Baltimore — Baltimore, Maryland
  • Saint Agnes Hospital — Baltimore, Maryland
  • MedStar Franklin Square Medical Center/Weinberg Cancer Institute — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Maryland:
  • UM Upper Chesapeake Hematology and Oncology - Aberdeen — Aberdeen, Maryland
  • University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
  • Greater Baltimore Medical Center — Baltimore, Maryland
  • Sinai Hospital of Baltimore — Baltimore, Maryland
  • MedStar Franklin Square Medical Center/Weinberg Cancer Institute — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06058377
Sites in Maryland:
  • UM Upper Chesapeake Hematology and Oncology - Aberdeen — Aberdeen, Maryland
  • University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
  • Mercy Medical Center — Baltimore, Maryland
  • Sinai Hospital of Baltimore — Baltimore, Maryland
  • Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

E-Mindfulness Approaches for Living After Breast Cancer

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …

Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Maryland:
  • Maryland Proton Treatment Center — Baltimore, Maryland
  • University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
  • Sinai Hospital of Baltimore — Baltimore, Maryland
  • MedStar Franklin Square Medical Center/Weinberg Cancer Institute — Baltimore, Maryland
  • MedStar Good Samaritan Hospital — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…

Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in Maryland:
  • Research Site — Annapolis, Maryland
  • Research Site — Baltimore, Maryland
  • Research Site — Baltimore, Maryland
  • Research Site — Bethesda, Maryland
  • Research Site — Lutherville, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in Maryland:
  • Holy Cross Hospital ( Site 0069) — Silver Spring, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Maryland:
  • Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine…

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT06016738
Sites in Maryland:
  • Clinical Trial Site — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in Maryland:
  • Greenebaum Comprehensive Cancer Center ( Site 0036) — Baltimore, Maryland
  • Mercy Medical Center - Baltimore-Medical Oncology and Hematology ( Site 0028) — Baltimore, Maryland
  • Holy Cross Hospital ( Site 0073) — Silver Spring, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after…

Sponsor: Hoffmann-La Roche
NCT ID: NCT05894239
Sites in Maryland:
  • Medstar Research Institute — Hyattsville, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Maryland:
  • University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
  • Walter Reed National Military Medical Center — Bethesda, Maryland
  • National Institutes of Health Clinical Center — Bethesda, Maryland
  • UPMC Western Maryland — Cumberland, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…

Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Maryland:
  • The John Hopkins Hospital — Baltimore, Maryland
  • Maryland Oncology Hematology- Columbia — Rockville, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has sprea…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03606967
Sites in Maryland:
  • Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receiv…

Sponsor: Biostar Pharma, Inc.
NCT ID: NCT06764940
Sites in Maryland:
  • The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well…

Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT05748834
Sites in Maryland:
  • Maryland Oncology Hematology — Columbia, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Eligible patients with stage 2 and 3 triple negative breast cancer will be treated with 4 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab. A PET scan will be performed at baseline and after 1 cycle of therapy. A breast MRI will …

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06245889
Sites in Maryland:
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These ce…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01174121
Sites in Maryland:
  • National Institutes of Health Clinical Center — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic …

Sponsor: Orano Med Theranostics, SAS
NCT ID: NCT05283330
Sites in Maryland:
  • Advanced Molecular Imaging and Therapy — Glen Burnie, Maryland
  • United Theranostics - Chesapeake — Glen Burnie, Maryland
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling…

Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT05029999
Sites in Maryland:
  • Johns Hopkins University — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line. The antibody …

Sponsor: A&G Pharmaceutical Inc.
NCT ID: NCT05627960
Sites in Maryland:
  • University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
View on ClinicalTrials.gov →

Showing 25 of 33 trials with sites in Maryland. See all breast cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10